



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2019





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

May 2019

N = 7424



Health Authority	Male	Female	All
FRASER	1429	435	1864
INTERIOR	414	98	512
NORTHERN	130	88	218
VANCOUVER COASTAL	3411	454	3865
VANCOUVER ISLAND	765	162	927
	6149	1237	7386
		Unknown/not stated:	38
		Total:	7424

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2014 - May 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2014 - May 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (May 2014 - May 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (May 2014 - May 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (May 2014 - May 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(May 2014 - May 2019)






1.8 Active and Inactive Participants (May 2014 - May 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2014 - May 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2014 - May 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(May 2014 - May 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (May 2014 - May 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2014 - May 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2014 - May 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2014 - May 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2014 - May 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(May 2014 - May 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts
(May 2014 - May 2019)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(May 2014 - May 2019)






1.20 Cumulative Resistance Testing Results by Resistance Category (May 2014 - May 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2014 - May 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	3	840	5	46	3
1988	28	7	0	7	7	450	7	<40	3
1989	26	53	1	54	44	480	53	<40	3
1990	25	53	1	54	40	490	52	<40	3
1991	25	38	3	41	29	570	39	<40	3
1992	25	63	5	68	47	580	65	<40	3
1993	24	137	16	153	133	560	147	<40	3
1994	23	81	13	94	75	540	90	<40	3
1995	22	126	23	149	123	570	140	<40	3
1996	20	349	54	403	324	585	384	<40	3
1997	18	294	34	328	282	610	317	<40	3
1998	17	199	44	243	202	540	237	<40	3
1999	18	164	37	201	164	560	191	<40	3
2000	18	126	32	158	134	580	149	<40	3
2001	17	122	32	154	120	540	144	<40	3
2002	16	126	26	152	121	560	146	<40	3
2003	16	161	30	191	152	625	184	<40	3
2004	15	167	39	206	172	605	197	<40	3
2005	14	189	45	234	188	610	220	<40	3
2006	13	192	43	235	195	600	222	<40	3
2007	12	260	51	311	258	620	293	<40	3
2008	11	292	71	363	300	660	343	<40	3
2009	10	323	74	397	329	670	382	<40	3
2010	9	277	71	348	292	630	336	<40	3
2011	8	335	76	411	330	670	385	<40	3
2012	7	280	67	347	280	700	327	<40	3
2013	6	275	65	340	283	670	325	<40	3
2014	5	286	55	341	264	730	313	<40	3
2015	4	293	53	346	285	660	327	<40	3
2016	3	289	60	349	276	640	323	<40	3
2017	2	244	39	283	237	630	269	<40	3
2018	1	232	57	289	247	630	284	<40	3
2019	0	115	28	143	137	520	139	<40	3
Total:		6153	1245	7398					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7281	750	2385	<40	2109	610
FEB-2018	7245	763	1904	<40	1743	610
MAR-2018	7270	769	2050	<40	1830	614
APR-2018	7256	776	2080	<40	1842	620
MAY-2018	7274	773	2147	<40	1928	600
JUN-2018	7275	787	2003	<40	1786	610
JUL-2018	7285	785	2037	<40	1810	600
AUG-2018	7289	795	2092	<40	1873	620
SEP-2018	7244	795	2015	<40	1787	620
OCT-2018	7338	776	2170	<40	1944	610
NOV-2018	7343	781	2092	<40	1814	630
DEC-2018	7360	787	1747	<40	1534	620
JAN-2019	7398	792	2456	<40	2129	610
FEB-2019	7382	799	1854	<40	1563	620
MAR-2019	7425	790	2086	<40	1718	610
APR-2019	7381	796	2143	<40	1675	610
MAY-2019	7424	796	2124	<40	1622	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1428	3315	79	890	71	380
FEB-2018	1472	3112	79	1036	66	440
MAR-2018	1456	3198	75	59	70	485
APR-2018	1474	3163	73	459	63	497
MAY-2018	1462	3229	93	<40	82	455
JUN-2018	1472	3230	73	1080	70	440
JUL-2018	1472	3261	70	<40	55	570
AUG-2018	1501	3172	64	63	60	485
SEP-2018	1546	2985	88	220	82	415
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1483	3312	81	83	73	480
DEC-2018	1479	3347	57	355	46	495
JAN-2019	1470	3415	73	73	65	350
FEB-2019	1497	3334	74	83	65	580
MAR-2019	1460	3508	74	885	59	400
APR-2019	1497	3395	80	<40	68	490
MAY-2019	1456	3570	81	60	65	460

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7242	1428	12	12	193	127	56	13217
FEB-2018	7211	1472	11	27	125	169	-31	13254
MAR-2018	7231	1456	17	21	158	138	20	13281
APR-2018	7223	1474	12	15	154	161	-8	13303
MAY-2018	7244	1462	9	12	174	153	21	13328
JUN-2018	7240	1472	13	16	152	156	-4	13350
JUL-2018	7242	1472	13	13	165	155	2	13376
AUG-2018	7254	1501	9	27	158	159	12	13415
SEP-2018	7208	1546	14	15	155	195	-46	13441
OCT-2018	7307	1473	8	19	218	126	99	13477
NOV-2018	7317	1483	5	9	172	163	10	13503
DEC-2018	7334	1479	11	19	152	142	17	13528
JAN-2019	7368	1470	14	20	191	161	34	13563
FEB-2019	7356	1497	7	16	161	178	-12	13592
MAR-2019	7386	1460	15	13	188	146	30	13612
APR-2019	7345	1497	9	15	149	178	-41	13639
MAY-2019	7398	1456	10	20	195	149	53	13679

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	60	6718	448	55	7281	0.82%	92.27%	6.15%	0.76%	100.00%
FEB-2018	64	6672	450	59	7245	0.88%	92.09%	6.21%	0.81%	100.00%
MAR-2018	62	6699	453	56	7270	0.85%	92.15%	6.23%	0.77%	100.00%
APR-2018	61	6689	449	57	7256	0.84%	92.19%	6.19%	0.79%	100.00%
MAY-2018	68	6693	455	58	7274	0.93%	92.01%	6.26%	0.80%	100.00%
JUN-2018	62	6709	447	57	7275	0.85%	92.22%	6.14%	0.78%	100.00%
JUL-2018	53	6719	458	55	7285	0.73%	92.23%	6.29%	0.75%	100.00%
AUG-2018	54	6725	454	56	7289	0.74%	92.26%	6.23%	0.77%	100.00%
SEP-2018	53	6678	456	57	7244	0.73%	92.19%	6.29%	0.79%	100.00%
OCT-2018	53	6757	474	54	7338	0.72%	92.08%	6.46%	0.74%	100.00%
NOV-2018	53	6765	475	50	7343	0.72%	92.13%	6.47%	0.68%	100.00%
DEC-2018	52	6782	477	49	7360	0.71%	92.15%	6.48%	0.67%	100.00%
JAN-2019	54	6805	486	53	7398	0.73%	91.98%	6.57%	0.72%	100.00%
FEB-2019	52	6789	492	49	7382	0.70%	91.97%	6.66%	0.66%	100.00%
MAR-2019	58	6827	490	50	7425	0.78%	91.95%	6.60%	0.67%	100.00%
APR-2019	56	6786	491	48	7381	0.76%	91.94%	6.65%	0.65%	100.00%
MAY-2019	54	6834	491	45	7424	0.73%	92.05%	6.61%	0.61%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3314 47%	9 32%	3070 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3628 51%
FEB-2018	13 35%	3315 47%	12 32%	3073 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3578 51%
MAR-2018	10 37%	3334 47%	10 37%	3099 44%	0 0%	59 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3564 50%
APR-2018	5 23%	3342 47%	5 23%	3111 44%	0 0%	55 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3534 50%
MAY-2018	9 39%	3351 48%	8 35%	3125 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3505 50%
JUN-2018	7 35%	3365 48%	7 35%	3142 45%	0 0%	53 1%	0 0%	5 0%	0 0%	3 0%	1 5%	379 5%	12 60%	3474 49%
JUL-2018	7 28%	3394 48%	7 28%	3172 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3445 49%
AUG-2018	13 33%	3393 48%	14 36%	3181 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3414 48%
SEP-2018	4 15%	3377 48%	3 12%	3162 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3365 48%
OCT-2018	11 31%	3418 48%	9 26%	3205 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3382 47%
NOV-2018	9 35%	3428 48%	8 31%	3214 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3353 47%
DEC-2018	8 32%	3446 48%	8 32%	3233 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3350 47%
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3360 47%
FEB-2019	13 45%	3466 48%	12 41%	3265 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3311 46%
MAR-2019	6 30%	3482 48%	6 30%	3285 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3314 46%
APR-2019	11 41%	3479 48%	11 41%	3287 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	587 8%	14 52%	3259 45%
MAY-2019	13 33%	3507 49%	13 33%	3315 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	591 8%	22 56%	3262 45%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3704	52%
FEB-2018	24	65%	3672	52%
MAR-2018	17	63%	3670	52%
APR-2018	17	77%	3656	52%
MAY-2018	14	61%	3651	52%
JUN-2018	13	65%	3651	52%
JUL-2018	18	72%	3648	52%
AUG-2018	25	64%	3647	52%
SEP-2018	22	85%	3625	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3669	51%
DEC-2018	17	68%	3671	51%
JAN-2019	27	77%	3699	51%
FEB-2019	16	55%	3680	51%
MAR-2019	14	70%	3710	51%
APR-2019	16	59%	3675	51%
MAY-2019	26	67%	3689	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1313 45%	7 70%	1414 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1255 44%	15 100%	1420 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1243 43%	10 91%	1438 50%	0 0%	187 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1220 43%	11 100%	1435 50%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1204 42%	5 100%	1438 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1185 42%	11 92%	1428 51%	0 0%	175 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1168 42%	7 70%	1439 52%	1 10%	168 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1423 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1405 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1446 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1054 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1033 39%	7 70%	1480 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 9%	1035 39%	10 91%	1481 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	3 50%	778 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	769 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	757 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	724 36%	1 50%	313 16%
JUL-2018	3 60%	722 36%	0 0%	243 12%	0 0%	717 36%	2 40%	313 16%
AUG-2018	2 100%	714 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	323 17%
DEC-2018	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	320 17%
JAN-2019	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	3 75%	661 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	4 100%	645 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	5 100%	646 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2003 60%	8 42%	630 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2023 60%	6 26%	640 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2058 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2102 61%	4 33%	653 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2136 61%	4 20%	664 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	8 73%	2168 62%	2 18%	672 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2202 62%	4 33%	674 19%	0 0%	42 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2252 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	704 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	720 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2439 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2490 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	7 54%	2504 64%	3 23%	740 19%	0 0%	36 1%	3 23%	636 16%
MAY-2019	0 0%	27 1%	18 67%	2566 65%	6 22%	745 19%	0 0%	37 1%	3 11%	632 16%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2004	27.52	1644	22.58	2592	35.60	117	1.61	55	0.76	869	11.94
FEB-2018	1961	27.07	1629	22.48	2610	36.02	116	1.60	59	0.81	870	12.01
MAR-2018	1974	27.15	1615	22.21	2644	36.37	113	1.55	56	0.77	868	11.94
APR-2018	1929	26.58	1596	22.00	2696	37.16	114	1.57	57	0.79	864	11.91
MAY-2018	1919	26.38	1575	21.65	2733	37.57	114	1.57	58	0.80	875	12.03
JUN-2018	1903	26.16	1563	21.48	2785	38.28	113	1.55	57	0.78	854	11.74
JUL-2018	1886	25.89	1566	21.50	2814	38.63	110	1.51	55	0.75	854	11.72
AUG-2018	1862	25.55	1549	21.25	2860	39.24	111	1.52	56	0.77	851	11.68
SEP-2018	1825	25.19	1532	21.15	2878	39.73	109	1.50	57	0.79	843	11.64
OCT-2018	1849	25.20	1529	20.84	2946	40.15	104	1.42	54	0.74	856	11.67
NOV-2018	1842	25.09	1523	20.74	2967	40.41	106	1.44	50	0.68	855	11.64
DEC-2018	1835	24.93	1511	20.53	3006	40.84	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.78	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.45	1479	20.04	3082	41.75	99	1.34	49	0.66	868	11.76
MAR-2019	1796	24.19	1474	19.85	3137	42.25	99	1.33	50	0.67	869	11.70
APR-2019	1767	23.94	1460	19.78	3148	42.65	100	1.35	48	0.65	858	11.62
MAY-2019	1776	23.92	1447	19.49	3203	43.14	97	1.31	45	0.61	856	11.53

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	3	4	368
MAY-2019	20	1	0	6	8	4	440

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11957	3652
FEB-2018	11987	3667
MAR-2018	12015	3697
APR-2018	12047	3727
MAY-2018	12082	3752
JUN-2018	12094	3755
JUL-2018	12120	3779
AUG-2018	12134	3774
SEP-2018	12157	3795
OCT-2018	12179	3798
NOV-2018	12216	3817
DEC-2018	12220	3812
JAN-2019	12262	3839
FEB-2019	12273	3841
MAR-2019	12308	3876
APR-2019	12341	3905
MAY-2019	12368	3917

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
May 2019

N = 7424

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	11	13	*
	50+	26	37	*
	Total HSDA:	43	56	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	98	54	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	365	490	281	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	43
	50+	*	*	91
Total HSDA:	192	255	148	
Total HA:		674	899	512

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	64	65	*
	35-49	176	198	*
	50+	429	631	*
Total HA:		674	899	512

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	537	719	414
Female	137	180	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	512	54	600	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	10
	5 years or more	11	7
	<5 years	14	12
	Total HSDA:	43	29
KOOTENAY BOUNDARY	10 years or more	46	33
	5 years or more	13	10
	<5 years	15	11
	Total HSDA:	74	54
OKANAGAN	10 years or more	227	167
	5 years or more	65	52
	<5 years	73	62
	Total HSDA:	365	281
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	107	74
	5 years or more	39	35
	<5 years	46	39
	Total HSDA:	192	148
Total HA:		674	512

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	398	284
	5 years or more	128	104
	<5 years	148	124
Total HA:		674	512

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	41	59	12	25
KOOTENAY BOUNDARY	69	121	21	44
OKANAGAN	212	913	57	284
THOMPSON/CARIBOO/SHUSWAP	131	500	39	136
Total:	453	1593	129	489

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	99

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	28	30	18
	35-49	108	118	83
	50+	225	299	172
	Total HSDA:	368	454	280
FRASER NORTH	0-19	10	10	*
	20-34	107	108	*
	35-49	355	388	*
	50+	537	857	*
	Total HSDA:	1009	1363	772
FRASER SOUTH	0-19	7	7	*
	20-34	115	117	*
	35-49	342	388	*
	50+	521	770	*
	Total HSDA:	985	1282	812
Total HA:		2362	3099	1864

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	24	24	13
	20-34	250	255	181
	35-49	805	894	637
	50+	1283	1926	1033
Total HA:		2362	3099	1864

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1795	2377	1429
Female	567	722	435

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1864	51	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	207	159
	5 years or more	81	62
	<5 years	80	59
	Total HSDA:	368	280
FRASER NORTH	10 years or more	541	387
	5 years or more	256	205
	<5 years	212	180
	Total HSDA:	1009	772
FRASER SOUTH	10 years or more	530	423
	5 years or more	225	183
	<5 years	230	206
	Total HSDA:	985	812
Total HA:		2362	1864

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1278	969
	5 years or more	562	450
	<5 years	522	445
Total HA:		2362	1864

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	489	32	68
FRASER NORTH	248	1548	49	242
FRASER SOUTH	212	1439	46	462
Total:	600	3476	127	772

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	195
FRASER NORTH	635
FRASER SOUTH	495
Total:	1325

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	62
	50+	*	*	201
	Total HSDA:		334	480
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		168	217
VANCOUVER	0-19	35	37	7
	20-34	439	452	316
	35-49	1401	1579	1027
	50+	2776	4724	2100
	Total HSDA:	4651	6792	3450
Total HA:		5153	7489	3865

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	38	40	8
	20-34	489	503	353
	35-49	1522	1711	1122
	50+	3104	5235	2382
Total HA:		5153	7489	3865

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4539	6572	3411
Female	612	915	454

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3865	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	183	151
	5 years or more	83	69
	<5 years	68	63
	Total HSDA:	334	283
RICHMOND	10 years or more	*	70
	5 years or more	*	32
	<5 years	*	30
	Never on ART	*	0
Total HSDA:	168	132	
VANCOUVER	10 years or more	2680	1914
	5 years or more	1190	881
	<5 years	781	655
	Never on ART	0	0
Total HSDA:	4651	3450	
Total HA:	5153	3865	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	*	2135
5 years or more	*	982
<5 years	*	748
Never on ART	*	0
Total HA:	5153	3865

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	167	487	51	172
RICHMOND	43	285	11	93
VANCOUVER	590	10692	192	5304
Total:	800	11464	254	5569

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	116

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	70
	50+	*	*	168
	Total HSDA:		314	445
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		123	164
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		727	1029
Total HA:		1164	1638	927

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	102	108	*
	35-49	313	364	*
	50+	742	1159	*
Total HA:		1164	1638	927

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	959	1348	765
Female	205	290	162

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	927	54	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	168	139
	5 years or more	72	58
	<5 years	74	60
	Total HSDA:	314	257
NORTH VANCOUVER ISLAND	10 years or more	68	58
	5 years or more	32	25
	<5 years	23	20
	Total HSDA:	123	103
SOUTH VANCOUVER ISLAND	10 years or more	417	305
	5 years or more	154	128
	<5 years	156	134
	Total HSDA:	727	567
Total HA:		1164	927

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	653	502
5 years or more	258	211
<5 years	253	214
Total HA:	1164	927

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	850	74	199
NORTH VANCOUVER ISLAND	134	262	47	77
SOUTH VANCOUVER ISLAND	209	1761	43	550
Total:	534	2873	164	826

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	35
SOUTH VANCOUVER ISLAND	108
Total:	194

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	14
	50+	*	*	34
	Total HSDA:		71	109
NORTHERN INTERIOR	0-19	5	5	*
	20-34	20	22	*
	35-49	72	89	*
	50+	86	145	*
	Total HSDA:		183	261
Total HA:		294	418	218

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	34	37	*
	35-49	110	147	*
	50+	143	227	*
Total HA:		294	418	218

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	178	258	130
Female	116	160	88

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	218	50	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	19	10
	5 years or more	13	7
	<5 years	8	5
	Total HSDA:	40	22
NORTH WEST	10 years or more	32	23
	5 years or more	24	21
	<5 years	15	12
	Total HSDA:	71	56
NORTHERN INTERIOR	10 years or more	72	50
	5 years or more	59	52
	<5 years	52	38
	Total HSDA:	183	140
Total HA:		294	218

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	123	83
	5 years or more	96	80
	<5 years	75	55
Total HA:		294	218

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	62	6	7
NORTH WEST	71	161	13	31
NORTHERN INTERIOR	104	453	15	176
Total:	213	676	34	214

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	22
NORTHERN INTERIOR	18
Total:	46

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	21	37	*
	THOMPSON/CARIBOO/SHUSWAP	26	44	*
	Total HA:	59	100	41
FRASER	FRASER EAST	44	54	34
	FRASER NORTH	54	90	44
	FRASER SOUTH	70	103	49
	Total HA:	168	247	127
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	11	16	9
	VANCOUVER	495	855	395
	Total HA:	531	919	428
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	77	41
	NORTH VANCOUVER ISLAND	17	26	16
	SOUTH VANCOUVER ISLAND	36	79	28
	Total HA:	102	182	85
NORTHERN	NORTH EAST	10	12	8
	NORTH WEST	31	60	24
	NORTHERN INTERIOR	67	104	57
	Total HA:	108	176	89
Total:		968	1624	770

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	602	1032	474
Female	366	592	296

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	770	51	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

